spring-dermatology-skin-care-2018-tracks

33 / 35

Page 60
Notes:
alliedacademies
Journal of Dermatology Research and Skin Care | Volume 2
May 14-15, 2018 | Montreal, Canada
Spring Dermatology &
Skin Care Expo Conference
Based on broad personal experience in dermatology
and especially in the management of patients with
moderate to severe psoriasis (track of >20 years of serving
both inpatients and outpatients) new data from clinical
studies with ixekizumab is presented. This contains new
data on long-term-efficacy of ixekizumab, effectiveness
in special localizations (scalp psoriasis, nail psoriasis,
palmoplantar psoriasis, genital psoriasis) as well as safety
data and experiences on patients switched to ixekizumab
from other biologics. Personal clinical experience from
my specialized outpatient dermatology center (>300 non-
selected outpatients with moderate to severe psoriasis, >250
patients on biological therapies, >50 patients on ixekizumab)
is discussed. Focusing on a relevant number of patients
switched from secukinumab to ixekizumab due to first or
secondary loss of efficacy significant differences between
both IL-17A-inhibitors mainly in terms of efficacy and speed
of therapeutic response are shown. Finally, the correlation
between PASI-90-/PASI-100 response and significant changes
in DLQI is highlighted.
Speaker Biography
Norbert Behnke is currently working in private practice as a Psoriasis-Specialist in
Germany. She is a reviewer of multiple journals with editorial positions in others. Her
expertise includes an interest in the Dermatology and psoriasis of disease including
acne, wound healing and psoriasis.
e:
Lxekizumab in the management of on selected outpatients with moderate to severe psoriasis - New
data and personal clinical experience
Norbert Behnke
Dermatologist, Germany